Barclays’s Apellis Pharmaceuticals APLS Stock Holding History

Barclays’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,400	Closed	-$35.2K	–	5026
2025 Q4	$35.2K	Buy	+1,400	New	+$32.8K	﹤0.01%	4791
2023 Q4	–	Sell	-256,400	Closed	-$9.75M	–	5217
2023 Q3	$9.75M	Buy	+256,400	New	+$11.3M	0.01%	1006

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's APLS Position: Q2 2026 in Review

Barclays sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 98,327 shares — an estimated $3.96M sold.

Barclays first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $35.5M in Q4 2019. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Barclays reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Barclays sold 98,327 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.96M.
Barclays first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
Barclays's Apellis Pharmaceuticals position peaked at $35.5M in Q4 2019.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.